C-GSZWOrsoBio
energy metabolism, energy homeostasis, first-in-class therapies
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-GSZW
C-GSZWC-GSZWenergy metabolism, energy homeostasis, first-in-class therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-1180 after single- and multiple-ascending doses in healthy subjects.
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.
This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.
This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TLC-2716 after single- and multiple-ascending doses in healthy subjects.
Orsobio raises funds to advance mitochondrial protonophores for obesity | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1
Healthcare M&A Weekly: Key Transactions and Trends 9/10/24 About Experience People Insights LET'S TALK Insights September 10, 2024 A Look at Recent Transactions Shaping the Future of Healthcare This week's article provides a summary of recent healthcare M&A news for September 10, 2024. The healthcare industry is rapidly evolving, with the lines between the healthcare technology and services sectors blurring - creating the catalyst for innovation, transformation, and continued market activity. TripleTree's Healthcare M&A Weekly summarizes recent mergers, acquisitions
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences … development partnerships. At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor’s product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies. This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping compa … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ustralian and New Zealand Children’s Haematology / Oncology Group Autism Impact Fund Autobahn Therapeutics Autonomous Therapeutics Avalo Therapeutics Avance Clinical Avania Avecho Biotechnology Avenue Therapeutics Avenzo Therapeutics AVEO Oncology Aveta Biomics AviadoBio Avid Bioservices AVM Biotechnology Awakn Life Sciences Axovant Gene Therapies Axovia Therapeutics Axsome Therapeutics Ayala Pharmaceuticals Azura Ophthalmics AzurRx BioPharma Bachem Baili Biopharmaceutical Ba … -Fite BioPharma Canadian Neuromuscular Disease Registry CanariaBio Cancer Focus Fund Cancer Prevention and Research Institute of Texas Cancer Research UK Candel Therapeutics Cantargia Cantex Pharmaceuticals Capricor Therapeutics CARB-X Cardiff Oncology Cardinal Health Care Access Research Caris Life Sciences Carisma Therapeutics Carrick Therapeut
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions Clinical data for TLC-6740 demonstrate additive metabolic benefits in combination with tirzepatide Novel preclinical findings for TLC-1180 demonstrate exercise-mimetic, insulin-sensitiz
Longitude Capital: Venture Growth Investing in Healthcare ABOUT TEAM PORTFOLIO NEWS CONTACT LP LOGIN Select Page Investing in transformative healthcare companies. Strategy & Approach Longitude Capital specializes in making venture growth investments in biotechnology, medical technology, and health solutions companies that seek to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. We invest in both privately held and publicly traded companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $2 billion across six … zes returns to key stakeholders. Our company name was inspired by the Longitude Prize , a competition established by the British monarchy in 1714 to solve one of the greatest scientific problems of the day. Our Team, Your Partners Longitude Capital’s founders have been investing together since 2002. Our team has over 200 years of combined investing experience in the life sciences industry and has collaborated on over 90 new investments and 150 follow-on investments in the bio … nt practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund and he began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Hoffman – La Roche, and Novartis. Mr. Enright currently serves on the boards of BioAge Labs (BIOA), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Opna B … to Pequot Ventures, Mr. Galletti worked at Amerindo Investment Advisors, Vector Fund Management, and the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his career in the life sciences industry at APM, a management consultancy dedicated to improving operations performance within the patient care and procedural units of large acute-care hospitals. Mr. Galletti currently serves on the board of Murj. Selected prior board memberships include … n Pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and holds an MBA from St. Mary’s College. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor of numerous patents. — Focus Areas: Biotechnology Location: Menlo
PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Liver disease - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science Abo
🚀 Proud moment: SpinChip Diagnostics ASA is joining bioMérieux in a NOK 1.6bn transaction! A remarkable milestone for Norwegian medtech innovation. Almost a year ago, I shared news about… | Patrick Kartevoll LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any ti … w remote medical monitoring solution. The round was led by SPI MLP & ENERGY FUND LP and Bpifrance with participation from Critical Path Ventures https://lnkd.in/dqaaHMHd RDS Raises €14M in Series A Funding https://www.finsmes.com 4 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Refresh Miami 11,443 followers 8mo Report this post Significant news for South Florida's growing biotech ecosystem. Ascenta Capital , based in West Palm Beach, has su … Capital , based in West Palm Beach, has successfully closed its inaugural $325M fund focused on development-stage biotechnology companies. The firm was founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim , both former Moderna executives who bring deep operating and investment expertise. What makes this particularly noteworthy: Ascenta's team has contributed to 30+ approved medicines throughout their careers, and they've already deployed over $100M across six portfolio com … at are collectively running 14 clinical trials with 40+ pipeline programs. This fund close reinforces South Florida's emergence as a legitimate medtech hub. The region attracted $572.5M in medtech funding across 45 deals in 2024, with companies like Insightec, DermaSensor, and others leading the charge. The combination of institutional capital, experienced operators, and a growing talent base is creating real momentum in our biotech sector. Learn more about their portfolio an … Frazier Life Sciences , Andera Partners , Deep Track Capital, Bayern Kapital , Fund+, HTGF | High-Tech Gründerfonds (HTGF), OCCIDENT , and Seventure Partners . “This landmark financing round reflects the deep conviction these global healthcare investors have in Tubulis and the disrupIve potential of our ADC platforms,” says Dr. Dominik Schumache
Healthcare Private Placement and M&A Transactions Review Week Ending September 1, 2024 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending S … A venture funding in a deal led by Capricorn Partners on August 30, 2024. CARMA FUND Management, CRB Health Tech and IBB Ventures also participated in the round. The company is a developer of a data interface application that connects health-related data to smartphones, wearables and connected medical products. Roboligent: The company raised $2 million of venture funding from undisclosed investors on August 26, 2024. The company is an operator of a robotics business intended … pated in the round. The company is a developer of personalized digital wellness application designed for women’s health management. Deep Breath: The company raised an undisclosed amount of venture funding from Graduate Entrepreneur on August 29, 2024. The company is a developer of a decision support system intended for optimizing mechanical lung ventilation in the ICU. IRUBIS: The company raised an undisclosed amount of venture funding in a deal led by BioProcess360 on
Fibrosis and Inflammation About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery Travel Posters Poster Information Poster Titles Best of S … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press Fibrosis and Inflammation Drug Discovery in NASH, Lung Fibrosis, Inflammatory Bowel Disease and Autoimmunity 9/27/2023 - September 28, 2023 EDT Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging … rdiovascular disease. 3:20 PM Capture of the Membrane Proteome in Peptidisc and Application to Liver Fibrosis Franck Duong, PhD, Professor, Biochemistry & Molecular Biology, University of British Columbia , Prof , Biochemistry & Molecular Biology , Univ of British Columbia I will describe the cell surface membrane proteome we have identified on the fibrotic liver. This proteome is notoriously difficult to isolate because membrane proteins are hydrophobic and limited i
Matthew Young - OrsoBio Skip to content about team science pipeline news about team science pipeline news Mr. Young is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to Jazz
Rob Myers - BIO International Convention 2026 Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! Save the date: June 7-10, 2027 BIO is back in Philadelphia in 2027! June 7-10 | Philadelphia Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs International Visitors Why Attend Visa Invitation Letter Request Tips for International Visitors Share On Social Media For Press Media Resource Center Media Registration Engaging with the Media Request Media List Press Releases Stay in Touch Contact Us Join our mailing list … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … d his MD and Internal Medicine training at Western University, Gastroenterology fellowship at the University of Calgary, and Hepatology fellowship at the Université de Paris VI, and holds a master’s degree in Epidemiology from the University of Calgary. Sessions 23-Jun-2026 4:15 PM – 5:15 PM 32AB Beyond GLP-1s – New Mechanisms and Modalities for Metabolic Disease BIO DOUBLE HELIX SPONSORS Our sponsors help support BIO's mission to support and advocate for the biotechnol
News & Press - Nueva Bio Home About Founders News Contact us Home About Founders News Contact us Home Nueva Bio News & Press News & Press Follow our blog and stay up to date. Uncategorized OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders November 7, 2023 Ajay KS No Comments Uncategorized OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023 November 6, 2023 Ajay KS No Comments Uncatego
OrsoBio investment analysis --> --> Bay Bridge Bio Menu Blog About Biotech DCF tool Contact OrsoBio investment analysis November 6, 2023 This is not investment advice. We used AI and automated software tools for most of this research. A human formatted the charts based on data / analysis from the software, prompted the AI to do some editing, and did some light manual editing. We did some fact checking but cannot guarantee the accuracy of everything in the article. We do not have a position in or a relationship with the company. Overview OrsoBio, Inc. is a private clinical-stage biopharmaceutic … nce rate. Payer Mix: Assume 70% have insurance coverage. Discounts and Rebates: Apply a 30% discount/rebate overall. Peak Sales: Estimated $5.5B. These figures could vary widely in reality and should not be used for investment or clinical decisions. Analyze your company with our AI tools Get a report like this one for your company or portfolio. Includes excel files with valuation analysis. Contact us to learn more Contact us TLC-3595 in Type 2 diabetes Scientific thesis TLC-3
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
OrsoBio, Inc. | Research profile | Nature Index Skip to main content Advertisement Search Main Navigation Home News News home News Comment Data insights Dataviz Careers Q+A Archive Current Index Institution rankings Institution benchmarking Institution collaboration Country/territory rankings Country/territory benchmarking Country/territory collaboration Data visualizations Articles Research highlights Topics Topic explorer Nature Index topics Leading institutions by topic Leading countries/territories by topic Research leaders Research leaders home 2026 Research Leaders 2025 Research Leaders … nt bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more. Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions. Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises. Explore course catalogues and workshop agendas, enquire abo … 0,000 active job seekers per month that you can target directly with your role. Application response rates have increased by 28% on average over 2022 averages. Advertise your job roles on Nature Careers Recruitment subscriptions Building your employer brand Latest supplements Nature Index 2026 Chemistry Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind
OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company — Company to share preclinical data on TLC-065 at The Liver Meeting ® — Palo Alto, Calif. – November 2, 2022 – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition … bout Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs
An obesity drug biotech gets buy-in from Eli Lilly, venture firms | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Ex … its obesity drugs that targets the liver. The cash raised will help the company fund clinical studies in obesity, diabetes, nonalcoholic steatohepatitis, hypertriglyceridemia and other liver and kidney conditions. “While we’ve witnessed remarkable breakthroughs in the treatment of obesity and diabetes, notably with GLP-1 receptor agonists, there remains a high unmet need for effective and safe oral therapies that are complementary to, and can be used in combination with, thes
Home - Nueva Bio Home About Founders News Contact us Home About Founders News Contact us Home Nueva Bio Home Nurturing Innovation CONTACT US About NuevaBio is an investment company that was set up to found, seed and grow innovative companies that build upon the extensive experience of the Founders. Companies that were founded by and in which NuevaBio is a significant investor include OrsoBio and MitoPower. Founders Mani Subramanian Manoj Desai Gans Ganapati News OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders Novemb
TLC-6740 / OrsoBio TLC-6740 / OrsoBio - LARVOL DELTA Home Next Prev 1 to 25 Of 25 Go to page 1 April 18, 2026 Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study (ADA 2026) - P1 | "The liver-targeted mitochondrial protonophore TLC-6740 combined with TZP was well tolerated and produced greater weight loss and metabolic benefits than TZP alone. These findings support combining incretins with therapies that increase energy expenditure to improve weigh
Fenwick Represents OrsoBio in $67M Series B Funding | Fenwick Skip to main content Main navigation Back Services Services Corporate Capital Markets Compensation & Benefits Corporate Governance Corporate Venture ESG & Sustainability Mergers & Acquisitions Private Equity Private Investment Funds Public Companies SPACs Startup & Venture Capital Intellectual Property Copyright Patents & Emerging Technologies Privacy & Cybersecurity Technology Transactions Trademark Litigation Appellate Complex Litigation Consumer Class Actions & Mass Arbitration Copyright Litigation Cri … r Offices Service Innovation Community Social Impact Pro Bono Fenwick Community Fund Contact Us Subscribe Careers Careers Students Experienced Attorneys Business Professionals Current Openings Insights Insights Events Crypto Review 2026 CLE Speaker Series What's Trending Search Press Enter to search Clear Search Our Insights Experience Fenwick Represents OrsoBio in $67M Series B Funding Share September 5, 2024 Fenwick Represents OrsoBio in $67M Series B Funding Fenwick r
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders — TLC-6740 acquired as part of the mitochondrial protonophore program from Gilead Sciences in 2020 and data to be presented at The Liver Meeting® 2022 — Palo Alto, Calif. – November 2, 2022 – Or … bout Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs
OrsoBio | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas OrsoBio Website: OrsoBio Business Area(s) Metabolism Therapeutics Diabetes Description OrsoBio’s development programs address high unmet medical need in patients with severe metabolic disorders, including type 2 diabetes, severe hypertriglyceridemia, and congenital and acquired lipodystrophies. C
OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals — Company will present preclinical data at The Liver Meeting ® as it continues Phase 1 clinical trial for TLC-2716 — Palo Alto, Calif. – November 2, 2022 – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treat … bout Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs
OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes — Company announces positive Phase 1 clinical data of TLC-3595 to be presented at The Liver Meeting® 2022 — Palo Alto, Calif. – November 2, 2022 – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for seve … bout Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Eli Lilly Portfolio: 110 Companies & Co-Investors (2026) | VCBacked Skip to main content VCbacked Search Digest YC Research Log in Get Started Home / Directory / Investors / Eli Lilly Back to Investors Eli Lilly Portfolio Companies Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds. Last updated: June 2026 Eli Lilly Investment Overview Portfolio Companies 110 Total Invested $4.0B Average Investment $49.4M What Industries Does Eli Lilly Invest In? Biotechnology 21 Health Care 12 Medical 7 Therapeutics 6 Life Science 5 Oncolo … enzymes found in human physiology. San Diego, United States February 2024 $3.3M Grant Founder Contacts [email protected] [email protected] 19,000+ verified contacts Get Instant Access Firefly Bio Biotechnology Medical Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders. San Francisco, United States February 2024 $94.0M Series A Founder Contacts [email protected] [email p
%PDF-1.7 %���� 1185 0 obj > endobj xref 1185 120 0000000016 00000 n 0000004474 00000 n 0000004729 00000 n 0000004774 00000 n 0000004817 00000 n 0000004855 00000 n 0000005208 00000 n 0000005317 00000 n 0000005423 00000 n 0000005508 00000 n 0000005593 00000 n 0000005679 00000 n 0000005765 00000 n 0000005851 00000 n 0000005936 00000 n 0000006021 00000 n 0000006106 00000 n 0000006191 00000 n 0000006276 00000 n 0000006415 00000 n 0000006451 00000 n 0000006548 00000 n 0000006655 00000 n 0000006730 00000 n 0000006766 00000 n 0000007159 00000 n 0000007517 00000 n 0000007741 00000 n 0000008004 00000 n … 9906 Millimeters 1 False False Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 1245 0 obj > endobj 1246 0 obj >stream h���n�@��~����J���U�J�F����/y�Kaԯ�C ��� �4i�*���ؙ�����J�_�Y�v�`��T�Ƿ��$ ��� ��et9���ȧ�D_�>����ƊJ�G�D\��H�� ��6 ���m\rE�V0E��:Ǣ.��f:�|u#�21+�rۇ�n{���_��ͪ���-Q��4�L�N�NY�N�7�Nm-%�}�yY���>_�[��O/}�xճ��=]���O� d� �2@�+��?=�Q … a-Bold.pfb; Helvetica-Bold.pfm Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 1249 0 obj > endobj 1250 0 obj > endobj 1251 0 obj > endobj 1252 0 obj > endobj 1253 0 obj > endobj 1254 0 obj > endobj 1255 0 obj > endobj 1256 0 obj > endobj 1257 0 obj > endobj 1258 0 obj > endobj 1259 0 obj > endobj 1260 0 obj > endobj 1261 0 obj > endobj 1262 0 obj > endobj 1263 … 2631 Millimeters 1 False False Cyan Magenta Yellow Black Default Swatch Group 0 application/postscript xmp.iid:C26E2D290A5EEA11AFF2B5F089642432 xmp.did:C26E2D290A5EEA11AFF2B5F089642432 xmp.did:C26E2D290A5EEA11AFF2B5F089642432 xmp.did:C36E2D290A5EEA11AFF2B5F089642432 xmp.iid:C36E2D290A5EEA11AFF2B5F089642432 xmp.did:C26E2D290A5EEA11AFF2B5F089642432 saved xmp.iid:C26E2D290A5EEA11AFF2B5F089642432 2020-03-04T16:57:49+05:30 Adobe Illustrator CS6 (Windows) / saved xmp.iid:C36E2D290A … 2432 2020-03-04T16:58:24+05:30 Adobe Illustrator CS6 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 70 0 obj > endobj 71 0 obj >stream h���n�@��~����J���U�J�F����/y�Kaԯ�C ��� �4i�*���ؙ�����J�_�Y�v�`��T�Ƿ��$ ��� ��et9���ȧ�D_�>����ƊJ�G�D\��H�� ��6 ���m\rE�V0E��:Ǣ.��f:�|u#�21+
Team Home team Portfolio Media Investor Login Team We are strategists, drug developers, operators and deal-makers with experience at globally successful bio-pharma companies and financial firms. We deploy our skills on behalf of our portfolio companies. EVAN RACHLIN, MD Co-Founder and Managing Partner LORENCE KIM, MD Co-Founder and Managing Partner JEFF CHODAKEWITZ, MD Advisory Partner MICHAEL ROSENBLATT, MD Advisory Partner PAUL DEUTSCH, MD / PhD Advisory Partner DANIEL BLOOMFIELD, MD Advisory Partner JOHN GUTIERREZ, MD Principal Leighanne Oh, MS Vice President DAVE SHIELDS Chief Financial Of … of Medicine. He trained in Internal Medicine at NYU/Bellevue and completed his fellowship in Infectious Diseases at Yale. MICHAEL ROSENBLATT, MD Advisory Partner Michael Rosenblatt, MD is an Advisory Partner at Ascenta Capital. He has held major leadership roles in the pharmaceutical industry, academia, and biotech/venture. He was Chief Medical Officer of Merck (2009-2016) and of Flagship Pioneering (2016-2022). Prior to that he was Dean of Tufts University School of Medicin … of the Board of Scientific Counselors of two NIH institutes and was elected to Fellowship in the American Association for the Advancement of Science and the American College of Physicians. Dr. Rosenblatt serves as chairperson of the Drug Information Association (DIA) and the Prix Galien USA Awards Committee. He is a member of the Harvard Medical School Board of Fellows and on the research advisory committees of the Massachusetts General Hospital, Brigham and Women’s Hospital … aude from Columbia and received an MD magna cum laude from Harvard. Internship, residency, and endocrinology training were all at the Massachusetts General Hospital. He is the recipient of the Fuller Albright Award and the Vincent du Vigneaud Award for his research, and the Chairman’s Award from Merck. PAUL DEUTSCH, MD / PhD Advisory Partner Paul Deutsch, MD, PhD, is an Advisory Partner at Ascenta, joining after 31 years in Translational Medicine and Early Development at Merc … everal charitable organizations. in 1986, Dan founded the American-SouthAfrican Scholarship Association (ASASA) which provided university scholarshipsfor disadvantaged students in South Africa. In 2003, Dan became the Founding President of the Friends of MandelaRhodes Foundation ( https://american-friends-of-the-mrf.org ). Dan was also a Founding
%PDF-1.6 %���� 1818 0 obj >stream h�2463S0P���w�/�+Q0���L)�6467 ��T��$����` � endstream endobj 1819 0 obj >stream hޜ��r�ș�q�����L�b���$5UZ;3㚱㲜����"["b�P��l冶�$ז+H�m�Ӳ3�;+�Rc@$������ft���,U��J˞1*�e��U!8��S!�^�B����B+/�(�V+Ө�t�2��Z^�Kن��V�H�5��FY��uVY'�V��*��+T��|.��VV�v�J^l�r��ȇ��K���p%Q�R�9�FyݫF� .ȶ��E�T�Q����Cll딜B��M����Ry#�F�� �4rł�X9��N+�id��|�d�Ko�Rv�����(����Fˉ�d9;�2���K$�������%�(��C�*���l#����*ߞ��BȎ�o�5yGκ�d�%P¥�|_mNr�mN�r�mNn��ڜ�� ��[�Oj����#�婧�Lޛ.����U�xcu���{�9�g������u��ta��WI^7��C�}��Hs M�b:���|@��6_N��|��D$�N���:��%Ӛ|�|�ZI��oϿ˸��������CJ�?��:} �K�J�� ��Uw�揼�� … z4r9XNMcDF2KuxV2KuxV2KuxV2KuxVTh+repP6PD1OY+s8KcvU4LTnT9r0+PXtTFKp
ih//2Q== application/pdf 2551_Vijayakumar AASLD BioScience Communications uuid:f0e6aa4d-5a98-4ca3-a352-db2183c14a22 uuid:d67bd374-c596-41ff-9c42-e028fd94696a proof:pdf Microsoft® PowerPoint® for Microsoft 365 1 True False 2592.000000 1728.000000 Points Arial-BoldMT Arial Bold Open Type Version 7.00 False arialbd.ttf ArialMT Arial Regular Open Type Version 7.00 False arial.ttf Arial-BoldItalicMT Arial Bold
%PDF-1.5 %���� 71 0 obj 20465 endobj 70 0 obj > stream ����ExifII*��Duckyd��ohttp://ns.adobe.com/xap/1.0/ ��&Adobed� �-�=O���������� 0!1"#@A2$34%!"1AQ2# 0aqBRb$�r�3���CsT%�45 !1AQa"2 0qB����R#���b��r���3CScs�@�$��!1AQaq 0���������� ��)�e\�φ5>�\� �Ey�Z{�^Si7�Y�����ͭ�H��۔�̅K�qf�� (�I- �K.Ӭ��\�Uj(��57����������Z� … endobj 1102 0 obj > stream 2025-01-19T00:39:20-05:00 2025-01-19T00:39:20-05:00 application/pdf Antenna House PDF Output Library 7.3.1863 NAD+, ACMSD, DNA repair, MASLD/MASH, Mendelian randomization, human liver organoids Antenna House Formatter V7.3 MR1 Linux : 7.3.2.60453 (2023-03-06T13:41+09) 2025-01-19T00:39:20-05:00 ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH Yasmine J. Liu, Masaki Kimura, Xiaoxu Li, Jonathan Sulc, Qi Wang, Sandra Rodrí
Evan Rachlin, MD - OrsoBio Skip to content about team science pipeline news about team science pipeline news Evan Rachlin, MD, is the co-founder and a Managing Partner of Ascenta Capital. Evan was previously a Managing Director at Blackstone Life Sciences from 2019 to 2022. Prior to Blackstone, he was Head of Strategy (reporting to the CEO) at Moderna (NASDAQ: MRNA) from 2015 to 2019, where he led development of the company’s annual long-range plan and helped formulate portfolio strategy and execute equity financings. He was a Principal at Bain Capital Ventures from 2012 to 2015, and began his
News - OrsoBio Skip to content about team science pipeline news about team science pipeline news News PRESS RELEASE IN THE NEWS EVENTS PUBLICATION June 14, 2026 OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026 read more June 5, 2026 OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions read more February 10, 2026 OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertrigl
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life S
Science - Restore Energy Balance to Treat Metabolic Disorders Skip to content about team science pipeline news about team science pipeline news Restoring Energy Homeostasis to Treat Severe Metabolic Disorders OrsoBio’s development programs address high unmet medical need in patients with severe metabolic disorders, including obesity, type 2 diabetes, severe hypertriglyceridemia, and MASH. Our programs address the root cause of organ dysfunction by modulating fundamental metabolic pathways with four highly targeted and complementary mechanisms: 0 % Prevalence of obesity in the United States 0 M
Skip to main content Toggle navigation Search Home Home Type here to filter the list Clinical Practice Guideline Saturday, Jun 13th 4:30 PM - 6:00 PM CT CPG01 - Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline Location: Room W375C Clinical Practice Guideline Chair: Stephanie A. Roberts, MD (she/her/hers) – Boston Children's Hospital Clinical Practice Guideline Chair: Ana Claudia Latronico, MD, PhD (she/her/hers) – Sao Paulo Medical School, Sao Paulo University Clinical Practice Guideline Moderator: Roma Gianchandani, 211322 Clinical Practice Guidelin … d Pituitary Debate Saturday, Jun 13th 10:45 AM - 10:55 AM CT DB01 - Remarks and Award Presentations Location: Room W375C Remarks: Carol A. Lange, PhD (she/her/hers) – University of Minnesota Diabetes and Vascular Disease Saturday, Jun 13th 10:45 AM - 12:15 PM CT DB01 - Hypercortisolism in Uncontrolled Type 2 Diabetes: Pathogenic Driver or Bystander? Location: Room W375C Debate Moderator: Alvin C. Powers, MD – Vanderbilt University Medical Center Diabetes and Vascu … n 13th 10:45 AM - 10:55 AM CT DB01 - Vigersky Outstanding Clinical Practitioner Award Presentation Location: Room W375C Awardee: Lisa Nachtigall, MD (she/her/hers) – Mass General Brigham Pituitary Center Diabetes and Vascular Disease Saturday, Jun 13th 10:45 AM - 12:15 PM CT DB01-01 - Hypercortisolism in Uncontrolled Type 2 Diabetes: Pathogenic Driver or Bystander? Location: Room W375C Debate Speaker: Marie E. McDonnell, MD – Brigham and Women's Hospital Diabe … and Vascular Disease Sunday, Jun 14th 10:30 AM - 10:35 AM CT DB02 - Remarks and Award Presentations Location: Room W375C Remarks: Carol A. Lange, PhD (she/her/hers) – University of Minnesota Adipose Tissue_Appetite_and Obesity Sunday, Jun 14th 10:30 AM - 12:00 PM CT DB02 - Low Testosterone in Obesity: Should We Treat or Not? Location: Room W375C Debate Moderator: Stephen R. Hammes, PhD,MD – University of Rochester Adipose Tissue_Appetite_and Obesity CE: 1.5 … - 10:35 AM CT DB02 - Richard E. Weitzman Outstanding Early Career Investigator Award Location: Room W375C Awardee: Katrin Svensson, Associate Professor – Stanford University Adipose Tissue_Appetite_and Obesity Sunday, Jun 14th 10:30 AM - 12:00 PM CT DB02-01 - Low Testosterone in Obesity: Should We Treat or Not? Location: Room W375C Debate
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences … development partnerships. At the clinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor’s product or technology, often covering Phase I, Phase II, and Phase III trials. These agreements are frequently multi-component, involving collaborative R&D, co-development, and commercialization strategies. This report provides detailed intelligence on the latest clinical-stage agreements in the healthcare sector, helping compa … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ustralian and New Zealand Children’s Haematology / Oncology Group Autism Impact Fund Autobahn Therapeutics Autonomous Therapeutics Avalo Therapeutics Avance Clinical Avania Avecho Biotechnology Avenue Therapeutics Avenzo Therapeutics AVEO Oncology Aveta Biomics AviadoBio Avid Bioservices AVM Biotechnology Awakn Life Sciences Axovant Gene Therapies Axovia Therapeutics Axsome Therapeutics Ayala Pharmaceuticals Azura Ophthalmics AzurRx BioPharma Bachem Baili Biopharmaceutical Ba … -Fite BioPharma Canadian Neuromuscular Disease Registry CanariaBio Cancer Focus Fund Cancer Prevention and Research Institute of Texas Cancer Research UK Candel Therapeutics Cantargia Cantex Pharmaceuticals Capricor Therapeutics CARB-X Cardiff Oncology Cardinal Health Care Access Research Caris Life Sciences Carisma Therapeutics Carrick Therapeut
Edd Fleming, MD - OrsoBio Skip to content about team science pipeline news about team science pipeline news Edd Fleming, M.D. is the Executive Vice President, Commercialization at Enavate Sciences. He is integral to the origination, diligence and selection of Enavate investments and support of the Enavate portfolio of companies, including strategic planning, governance, partnerships and commercialization. Edd currently serves on the board of directors of several Enavate portfolio companies, including OrsoBio, Sionna Therapeutics, Sudo Biosciences and Upstream Bio. Edd has spent more than 30 ye
OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025 - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025 Clinical and pharmacogenetic data confirm the safety and suitability of TLC-6740 for use in conjunction with GLP-1 receptor agonists and proton pump inhibitors across genomic profiles Preclinical studies demonstrate the potential of TLC-6740 and TLC-1180 to p
%PDF-1.6 %���� 729 0 obj > endobj xref 729 20 0000000016 00000 n 0000002033 00000 n 0000002099 00000 n 0000002380 00000 n 0000002523 00000 n 0000002567 00000 n 0000002613 00000 n 0000003358 00000 n 0000003823 00000 n 0000004270 00000 n 0000004717 00000 n 0000005168 00000 n 0000005611 00000 n 0000006070 00000 n 0000006536 00000 n 0000007015 00000 n 0000007100 00000 n 0000061747 00000 n 0000061987 00000 n 0000000696 00000 n trailer ]/Prev 5343561>> startxref 0 %%EOF 748 0 obj >stream h��XoL[U?����2���:t� L�`���� �c�|0�7XH��,���XqC�Hтā�B`��a#�n!�E� 誁" Qc��-��RJacj�KzϹ�{�=���=i_@ � … TAKARA PRINTING CO.,LTD. true 52c3302816f8181e35f8b69ea2c37a1805efb916 5344967 application/pdf 2025-09-09T17:50:15.003+09:00 false 2025-09-01T20:33:33.000+09:00 2025-09-01T20:33:33.000+09:00 2025-09-01T20:33:33.000+09:00 iText® Core 7.2.5 (production version) ©2000-2023 iText Group NV, TAKARA PRINTING CO.,LTD. endstream endobj 728 0 obj > endobj xref 0 729 0000000000 65535 f 0000062577 00000 n 0000062821 00000 n 0000062906 00000 n 0000062980 00000 n 0000083557 00000 n 000008
OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders Round co-led by Ascenta Capital and Woodline Partners LP Company to advance TLC-6740 into later-stage clinical trials and TLC-1180 and TLC-1235 into IND-enabling studies MENLO PARK
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBio MENLO PARK, Calif. – November 7, 2023 – OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biophar … technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. To learn more about Enavate, please visit www.enavatesciences.com . About Samsara BioCapital Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private ma
Orsobio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Orsobio, Inc. Startups | Holding Company | 2021 | California, United States | 10-50 | orsobio.com Startups | Holding Company | 2021 | California, United States | 10-50 | orsobio.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction OrsoBio is a clinical-stage biopharmaceutical company that focuses on developing therapies for patients with seve … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Orsobio Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR
Invest In OrsoBio Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About OrsoBio Stock Invest in or calculate the value of your shares in OrsoBio or other pre-IPO companies through EquityZen's platform. Get Started View More Companies OrsoBio Stock (ORSB) OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders. Invest Now Sell Shares About OrsoBio Stock Founded 2021 Headquarters Palo Alto, CA, US Industrie … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
Archana Vijayakumar, PhD - OrsoBio Skip to content about team science pipeline news about team science pipeline news OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more. Linkedin Instagram Facebook Youtube about our team science pipeline news Contact Us [email protected] © 2026 OrsoBio, Inc. | Privacy Policy - FCOI Policy Biotech Website Design about team science pipeline news about team science pipeline news Linkedin Instagram Facebook Youtube Search Recent News OrsoBio team members collaborated
OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders — $2.3 million SBIR grant from National Institute of Diabetes and Digestive and Kidney Diseases will fund preclinical development activities for novel compound TLC-1235 — Palo Alto, Cali … ed that it has secured a $2.3 million Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to fund IND-enabling activities for its compound, TLC-1235, a controlled-release mitochondrial protonophore (CRMP) based on Yale intellectual property. “Our research in rodent and nonhuman primate models of NAFLD/NASH and type 2 diabetes has shown that a controlled-release formulation of the mitochondrial proto … disorders for which there are currently limited effective treatments.” The SBIR grant will enable OrsoBio to advance TLC-1235 as a potential treatment to improve insulin sensitivity, NASH, and dyslipidemia in patients with severe lipodystrophies. Specifically, the funding will support initiation of IND-enabling activities, including synthesis of TLC-1235 and safety pharmacology and toxicology studies. “TLC-1235 provides a novel approach to addressing insulin resistance, which … MD, Chief Medical Officer of OrsoBio and Co-Principal Investigator on the SBIR grant. “This NIDDK funding is a recognition of the extensive research from the Shulman Lab that has elucidated the mechanism of action of TLC-1235 and enables us to advance the compound to clinical studies with a goal of improving outcomes in patients with lipodystrophies and other severe metabolic disorders.” About TLC-1235 TLC-1235 is a novel, controlled-release mitochondrial protonophore that h … bout Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stage
TLC-1180, a Protonophore, with Semaglutide Enhances Weight Loss and Preserves Lean Mass in DIO Mic (ObesityWeek 2025, Oral #013) - OrsoBio Skip to content about team science pipeline news about team science pipeline news News TLC-1180, a Protonophore, with Semaglutide Enhances Weight Loss and Preserves Lean Mass in DIO Mic (ObesityWeek 2025, Oral #013) OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more. Linkedin Instagram Facebook Youtube about our team science pipeline news Contact Us connect@orso
News - OrsoBio Skip to content about team science pipeline news about team science pipeline news News PRESS RELEASE IN THE NEWS EVENTS PUBLICATION June 14, 2026 OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026 read more June 5, 2026 OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions read more February 10, 2026 OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertrigl
Our Pipeline - OrsoBio Skip to content about team science pipeline news about team science pipeline news Our Pipeline OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more. OrsoBio’s therapies target fundamental pathways of energy metabolism, and our team of physicians and scientists draw on decades of drug development experience. Our Pipeline Mitochondrial protonophore TLC-6740 Mitochondrial protonophore TLC-1180 Mitochondrial protonophore TLC-1235 Obesity Mitochondrial protonophores to increase ener
OrsoBio - Developing Therapies to Treat Metabolic Disorders Skip to content about team science pipeline news about team science pipeline news Advancing first-in-class therapies to restore energy homeostasis our science our pipeline about us OrsoBio is developing novel approaches to treat patients with severe metabolic disorders, including obesity, diabetes, severe dyslipidemias, MASH, and more. OrsoBio’s therapies target fundamental pathways of energy metabolism, and our team of physicians and scientists draw on decades of drug development experience. Our Team The OrsoBio team is a group of fo
OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders - OrsoBio Skip to content about team science pipeline news about team science pipeline news News OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders — Company advances two clinical and two preclinical programs targeting fundamental aspects of energy metabolism — Palo Alto, Calif. – November 1, 2022 – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced four development programs that t
ENDO 2026 Skip to main content Toggle navigation Search Home Facebook Post Print G. Mani Subramanian, MD OrsoBio, Inc. Menlo Park, California, United States Disclosure information not submitted. Presentation(s): ORF30-06 - The Liver X Receptor Inverse Agonist TLC-2716 Reduces Triglycerides, Remnant Cholesterol, and Liver Fat in Patients with Severe Hypertriglyceridemia and Metabolic Dysfunction-Associated Steatotic Liver Disease Sunday, June 14, 2026 2:30 PM - 2:45 PM CT Designed by Cadmium | Website Technical Support | Give Feedback © Copyright 2026 Cadmium. All Rights Reserved.
Congratulations to OrsoBio G. Mani Subramanian Rob Myers, MD and team! Thrilled to learn that oral liver targeted mitochondrial therapeutics can bring positive signals on obesity and hepatic… | Takanori Takebe LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
Mani Subramanian, MD, PhD - OrsoBio Skip to content about team science pipeline news about team science pipeline news Dr. Subramanian has spent more than 20 years advancing first-in-class therapies to approval. He was previously Senior Vice President and Therapeutic Area Head for Liver Diseases at Gilead Sciences where he oversaw approval of multiple therapies for viral hepatitis (Sovaldi®, Harvoni®, Epclusa®, Vosevi®, Vemlidy®) and a portfolio of compounds in NASH and other liver diseases. Previously, he was at Human Genome Sciences where he developed albumin-fusion proteins and monoclonal an … ne training at University Hospitals of Cleveland (CWRU) and Infectious Diseases fellowship at NIAID, NIH. He holds a PhD degree from University of Michigan and MD from Armed Forces Medical College, India. OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more. Linkedin Instagram Facebook Youtube about our team science pipeline news Contact Us [email protected] © 2026 OrsoBio, Inc. |
OrsoBio | The Org Platform Enrich Pricing Log in Sign up OrsoBio 0 followers OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and p... Read more Industries Biotechnology , Health Care + 2 Headquarters Palo Alto, United States Employees 1-10 Links Org chart Teams Offices Positions ( 13 ) Unverified Org chart G. Mani Subramanian CEO 9 G. Mani Subramani
OrsoBio, Inc. Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo OrsoBio, Inc. OrsoBio, Inc. Menlo Park, CA Watchlist Export About Financials People Deals Funding About OrsoBio, Inc. Company overview OrsoBio, Inc. is a privately-held firm that operates clinical-stage biopharmaceutical services intended to develop therapies for organ dysfunctional. OrsoBio, Inc. was founded in 2021 by Gans Ganapati and Mani Subramanian. OrsoBio, Inc. headquarters are located in Menlo Park, California. OrsoBio, Inc. was formerly known as The Liver Company. Keywords Rev
Gans Ganapati - OrsoBio Skip to content about team science pipeline news about team science pipeline news OrsoBio is developing novel approaches to treat patients living with obesity and associated metabolic disorders, including diabetes, MASH, and more. Linkedin Instagram Facebook Youtube about our team science pipeline news Contact Us [email protected] © 2026 OrsoBio, Inc. | Privacy Policy - FCOI Policy Biotech Website Design about team science pipeline news about team science pipeline news Linkedin Instagram Facebook Youtube Search Recent News OrsoBio team members collaborated with Profes
Gans Ganapati - Nueva Bio Home About Founders News Contact us Home About Founders News Contact us Home Nueva Bio Gans Ganapati Gans Ganapati Gans Ganapati, MBA Gans Ganapati is Managing Partner of NuevaBio and a Co-Founder of OrsoBio and MitoPower. He has over 25 years of business leadership experience. He was VP of Corporate Development and a member of the founding management team of Adamas Pharmaceuticals (Nasdaq: ADMS), where he was closely associated with the development of GocovriTM and the outlicensing deal with Forest Laboratories leading to the launch of NamzaricTM. Previously he was a
Gans Ganapati - OrsoBio Skip to content about team science pipeline news about team science pipeline news Gans Ganapati, Co-Founder and Chief Business and Financial Officer of OrsoBio, brings over 25 years of business leadership experience. He was VP of Corporate Development and a member of the founding management team of Adamas Pharmaceuticals (Nasdaq: ADMS), where he was closely associated with the early development of Gocovri ® and the outlicensing of Namzaric ® to Forest Laboratories. Previously, he was a co-founder of HealthCare Global Enterprises (NSE:HCG), the largest provider of cancer
Apollo Therapeutics CEO talks business model and phase 2 trials | Apollo Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or si … mo Report this post TCG Crossover Raises $1.3B for Its Third Biotech Investment Fund Over Four Years TCGX has closed its third fund in about four years, securing $1.3 billion and bringing its total capital under management to $3.1 billion. The round was backed by a mix of existing and new institutional, foundation, and endowment investors. Company leadership emphasized that surpassing their target demonstrates deep investor confidence in their strategy to back bold biotech in … fidence in their strategy to back bold biotech innovation. Key Points • The new fund exceeds TCGX’s second fund, which closed with $1 billion • TCGX has backed high-profile biotech startups across multiple therapeutic areas • As part of their latest move, Giuliano Marostica was promoted to managing partner Questions How does this latest fund reflect continued confidence in biotech innovation? What factors are driving sustained investment momentum across life sciences? “Exceed … g sustained investment momentum across life sciences? “Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach.” Chen Yu , M.D., founder and managing partner of TCGX, said in the release. Read the full article in the comment section #Biotech #VentureCapital #TCG #LifeSciences #Innovation #HealthcareInvesting #DrugDevelopment #Research #PrevailInfoWorks #CapitalGrowth 9 1 Comment Like Comment Share Copy Link … hs as before https://lnkd.in/gQN-m_Ya Samsara BioCapital eyes $200M opportunity fund https://lnkd.in/gJJWG9qf Samsara BioCapital eyes $200M opportunity fund endpoints.news 9 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kyle LaHucik 8mo Report this post Only a handful of freshman biotech venture funds hav
%PDF-1.6 %���� 22955 0 obj > endobj 22962 0 obj >/Filter/FlateDecode/ID[ ]/Index[22955 13]/Info 22954 0 R/Length 57/Prev 5716606/Root 22956 0 R/Size 22968/Type/XRef/W[1 2 1]>>stream h�bbd``b`_$߀��@��H0/��@��e&�H+ ������B�/@���� endstream endobj startxref 0 %%EOF 22967 0 obj >stream h��V�Ogk{ � �X �R�K�2�rZ��I���IUt���#�%{k�H1�,�/UA�vEX�@���4S7��-��c2C6�{_(e��k�}���� �.�9-#�Ǎ��� J����dϤ)S4�&� �[��nmg�5��.v�g�T Z�eL��QJ�p���Z�G�xY�Y R'�(�!��D9H���&��{���� P�� ���Y�7�&H�R 3�|lL���{G�O@Z��1S���Z������T 7�� G � U�{@_$k6T�١����� >/Metadata 1011 0 … |B��}ai �L�d|�ɢ�7� ��=�/*�A�a���֝g/P���R זMI�9�����k.]��.}omcSܺ2+(fT�6�rFP��]�����'/)�PۀV���^\fMw��8�L�-]w�^�ʿCqpppppp~P����T�^[Z�6+- A��^Q�\fT������� �KgrPm�ӸJS�vԬw�V � �f2�f�Ebcޗ��S� �� �\��ZR| J���1���/��n(�|�w�� ˋ��R�D"��;��ߋN�8�ݵm�c���S������[aaƷ�P�s,�G |�n J��LS�ϟ�ds`˒D������eP�D�L�dT�(����3\��� � N� ��K ��B{ �r�Vt�8���qw._p��Y��(�G�*�"���P�:𭣭-l��|c��4`��� �@LMڡjlzZ�F�XT5s��.Z���mP"���~����%��n}gU �О��!\9e�V�����-mߝ� … T17:34:59.000+09:00 2024-09-05T17:34:59.000+09:00 2024-09-04T10:10:10.000+09:00 application/pdf 2024-09-05T17:53:43.203+09:00 uuid:e1931cfb-1251-4f67-add7-278707b226df uuid:8ee43a98-90bc-4b44-a95d-e1f8a55a06f9 3 Adobe PDF Library 20.13.106 endstream endobj 1012 0 obj >stream hޜ��nS1�_�o{�lKU7,�T;Ģb��o�3s��(?^ݱb �7w|Cԋ��h ���nd���vd�V�/��Nu]������E Ie�#c��ۑ!Ys,�Z �!ٺ��כ�ђ8W�3\sQ�3�4�|x�}�����8^�}����s����ޢ�E㔈�A��W|�}���u�������qJ� �۶�L�q�-�z��=��~�+�p��op��p :�
%PDF-1.5 %���� 1 0 obj > endobj 6 0 obj > endobj 2 0 obj > endobj 3 0 obj > stream application/pdf Shaping the Future: Innovations and Trends in Obesity Treatment x-unknown Other Andy T. Hsieh 2025-02-27T16:00:26-05:00 Apache FOP Version 2.10 1.5 Phone: +1 312 364 5051; Email: [email protected] Partner True https://williamblair.bluematrix.com PDF Print BlueMatrix 2025-02-27T16:00:26-05:00 2025-02-27T16:00:26-05:00 endstream endobj 4 0 obj > endobj 5 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 … :162ec2f7-070a-4d5d-9662-60ad83555773 uuid:194a5079-070e-4dba-aea4-ad5e9c26e471 application/pdf Greenwood, Dalton Adobe PDF Library 23.6.96 endstream endobj 1974 0 obj > stream H�\�An�@E�����"�DB� ;���$� Cۃ4�� �~��D$�����k�|����nr�G �}�ܱ��.�56� ©�e�ڮ�>����\�Y�����λ�8dU����e�7w�n�C����؆��'w�{��w��:��9��[��ʵ���Ƿ� \>�=��t��n����_�1�b�^2L3��2�M�u Y�H��U��Xe�o���=���O ���ËE:%�d~$?���O�g�3xCހ��-���T�r�tJ\� ��lds��k�:�����������̞��B��(Y�\K���K�%t�].�B~�K��o �� … 8�Cw�1:Jw� t; ��t�n������k�_n�� ��?�H�! endstream endobj 2204 0 obj > stream application/postscript Print Flynn, CJ 2011-06-17T12:12:30-05:00 2011-06-17T12:12:30-05:00 2011-06-17T12:12:30-05:00 Adobe Illustrator CS4 xmp.iid:3457E67AEA98E0119000FF0CB9A746BC xmp.did:3457E67AEA98E0119000FF0CB9A746BC uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:09D7664F4485E011A73ED89CA069B566 xmp.did:09D7664F4485E011A73ED89CA069B566 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf c … A73ED89CA069B566 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:0 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-0
Metabolic Collaboration and Licensing Agreements Benchmark Report 2026: Access Structured Analysis of 639 - Financial Terms, Upfronts, Stage, Asset Type, Milestones, and Royalties Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management B … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets open in 47m UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets open in 47m FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3201 +0.0003 +0.03% GBP/EUR 1.1599 +0.0002 +0.02% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,022.80 -24.80 -0.61 … im Eracal Therapeutics Eton Pharmaceuticals European Union Regional Development Fund European Wellness Biomedical Group EVA Pharma EverlyWell Eversana EVerZom Evgen Pharma Evidation Health Evo Foods EVOQ Therapeutics Evotec Evozyne Ewopharma ExCEEd Orphan Fermbox Bio First Wave Bio FitBit Flagship Biosciences G3 Therapeutics G42 Healthcare Gain Therapeutics Galapagos Galectin Therapeutics Galmed Pharmaceuticals Gan & Lee Gannex Pharma Gastrologix GATC Health GC Pharma GE Heal
--> » OrsoBio raises $60m to advance treatment for obesity and associated disorders --> --> OrsoBio raises $60m to advance treatment for obesity Pharmaceutical Business review is using cookies Continue Learn More Close ☰ Search × Home About Us Add Company Advertise with us Contact us Events Suplpiers News Clinical Trials Drug Discovery Packaging & Supply Chain Production & Sales Regulation Advertise With Us Advertise on our extensive network of industry websites and newsletters. Get the PBR newsletter Sign up to our free email to get all the latest PBR news. Home Dr … t Enrollment Human Trials Patient Enrollment US FDA approves Avacta Group’s IND application for AVA6000 Clinical Trials Patient Enrollment AM-Pharma enrols first patients in Covid-19 phase III trial Clinical Trials Patient Enrollment Regulation Regulation Drug Filing Approvals Rejections Marketing Authorisation Patents Lawsuits Drug Filing Viatris files applications in Japan for approval of Effexor to treat GAD Regulation Drug Filing Drug Manufacturing Scholar Rock submits ap
10-K false FY 0001744659 http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 0001744659 us-gaap:CommercialPaperMember 2023-01-01 2023-12-31 0001744659 us-gaap:RetainedEarningsMember 2024-12-31 0001744659 akro:AmendedSalesAgreementMember 2023-01-01 2023-12-31 0001744659 akro:CommonStockAvailableForAtmProgramMember akro:PfizerIncMember 2022-06-15 0001744659 us-gaap:FairValueInputsLevel3Member akro:WarrantLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 20 … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth compa … X, or placebo. The primary histology endpoint, for Cohort 1 only, to support an application for accelerated approval, is the proportion of patients experiencing ≥ 1-stage fibrosis improvement and resolution of MASH after 52 weeks of treatment. All patients in Cohort 1 and Cohort 2 will be evaluated for long-term clinical outcomes for up to 240 weeks of treatment. Results for the 52-week primary histology endpoint from the SYNCHRONY Histology trial are expected in the fi … welve years of market exclusivity from the approval date of a Biologics License Application, or BLA, in the United States. Our management team has extensive experience in drug discovery, development and commercialization, and has been involved in the approvals of more than 20 medicines. Our Chief Executive Officer, Andrew Cheng, MD, PhD, was formerly Chief Medical Officer at Gilead, and responsible for clinical development for Gilead's HIV program. Our Chief Development Offic … X, or placebo. The primary histology endpoint, for Cohort 1 only, to support an application for accelerated approval, is the proportion of patients experiencing ≥ 1-stage fibrosis improvement and resolution of MASH after 52 weeks of treatment. All patients in Cohort 1 and Cohort 2 will be evaluated for long-term clinical outcomes for up to
OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
OrsoBio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 28 Sep 2024 OrsoBio, Inc. Startups | Private Company | 2020 | California, United States | 10-50 | orsobio.com Startups | Private Company | 2020 | California, United States | 10-50 | orsobio.com Last update 28 Sep 2024 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with OrsoBio, Inc. Login to view more data 0 Patents (Medical) associated with OrsoBio, Inc. Logi … he GLP animal and Phase 1 CHIHUAHUA studies are intended to support the US IND9 application filing of DSR 2.0, planned for Q1 2023. Preparations ongoing to start the MOJAVE study, planned for Q2 2023, assuming FDA approval of the US IND application. The intention is to enroll 30 diuretic-resistant chronic heart failure patients with persistent congestion, with 20 patients randomized to DSR 2.0 administered via a peritoneal catheter on top of usual care for congestive heart fa … ta from the GLP animal studies are intended to support the filing of the US IND application, planned for Q1 2023. Outlook for 2023 2023 is a pivotal year for Sequana Medical as it builds upon the successful clinical data published for both programs in 2022. The Company is working towards the PMA submission for the alfapump program to the US FDA planned for H2 2023. For the DSR heart failure program, the key next step is the Phase 1/2a MOJAVE randomized controlled study expect … fficacy and safety endpoints from the North American pivotal POSEIDON study and submit for presentation at a forthcoming medical liver meeting in 2023. Top-line data from the US patient preference study expected in H2 2023. Heart failure program of DSR 2.0 – on track to start US Phase 1/2a MOJAVE study in Q2 2023: Top-line results from Phase 1 single-arm, open-label, single-dose study in Mexico (CHIHUAHUA) expected in Q1 2023. IND application filing to US FDA expected in Q1 2 … ability to raise additional capital and to refinance existing debt, in order to fund operations and assure the solvency of the Company until revenues reach a level to sustain positive cash flows. The impact of macroeconomic conditions and the geopolitical situation in Ukraine on the Company’s ability to secure additional financing rounds or under
OrsoBio begins subject dosing in type 2 diabetes therapy trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Ser
Rx Rundown: Biogen, Novartis, Arbutus Biopharma and more HAYMARKET MARKETING COMMUNICATIONS: Campaign US MM+M PRWeek Newsletters | Log In | Register Search for: News Agencies Five Things to Know Data/Analytics Campaigns Pharma Podcasts Policy Media Technology People Moves Rare Disease In-Depth MM+M Best Places to Work 2025 Career and Salary Survey 2025 Healthcare Marketers Trend Report 2025 MM+M/Publicis Health Innovation Survey 2025 Events MM+M Awards MM+M Media Summit AI Deciphered Pinnacle Awards MM+M 40 Under 40 2025 MM+M Transform MM+M Health Marketing Influencer 25 Women of Distinction W … s chief medical officer is leaving. Deals Abcam shareholders approved the proposal from Danaher to acquire all outstanding shares of the company for $5.7 billion. South Korea-based drugmaker Chong Kun Dang Pharmaceutical said it signed a $1.3 billion deal with Novartis to license out drug candidate CKD-510. Acumen Pharmaceuticals entered into a collaboration with Halozyme to develop a subcutaneous formulation o … on chip will be ready in a few years. Johnson & Johnson said it would submit an investigational device exemption application to the Food and Drug Administration in the second half of 2024 to initiate clinical trials for its general surgery robot. The Centers for Disease Control and Prevention said cases of syphilis among newborns are skyrocketing. OrsoBio , a biotech focused on obesity and metabolic disorders, received financial backing from& … dation created Blackbird Laboratories , supported by a $100 million fund, to create and retain more university-based startups in the Baltimore region. The state of Arkansas announced a $50 million grant of opioid settlement funds to create the National Center for Opioid Research & Clinical Effectiveness , which will be part of the Arkansas Children’s hospital system. Lexeo Therapeutics closed its $100 million initial public offering on th
Sponsors we work with Recruiting Trials Go Sponsors Why Engage With Us Our Investigators Sponsors, CROs and Partners Regional Health Statistics Diabetes and Obesity Investigators Grants Commercial Trials Participants Why Participate FAQ Videos Trial Sites Middlemore Hospital Whangārei Hospital About Us Management Governance Latest News Document Centre Annual Report Careers Celebrating Research Contact Us Home Sponsors Sponsors, CROs and Partnerships Sponsors, CROs and Partnerships Sponsors ACTT works with a substantial number of international and local sponsors. CRO’s Partnerships Faster Activ
OrsoBio, Inc. — Grokipedia Search ⌘K Suggest Edit Sign in Sign in History Founding and Early Development Funding and Milestones Scientific Approach Core Technologies Targeted Metabolic Pathways Pipeline Mitochondrial Protonophore Programs LXR Inverse Agonist Program ACC2 Inhibitor Program ACMSD Inhibition Program Leadership and Organization Key Executives Corporate Structure and Location Clinical Trials and Research Ongoing Phase 2 Trials Preclinical and Early-Stage Developments References Fact-checked by Grok 5 months ago OrsoBio, Inc. Ara Eve Leo Sal 1x OrsoBio, Inc. is a privately held, cli … , and breakthroughs are ideal Search first to check if it already exists Cancel Submit Summary Edit content (optional) Supporting sources (optional) Add another source What makes a great edit? Select the wrong text in the article first Add a source link so we can verify One fix per submission is easiest to review Cancel Submit Edit Something went wrong We couldn't submit your suggestion. Please try again. Try again Thank you! Grok will review your suggestion and add the artic … review your suggestion and add the article if it sees fit. View my suggestions Submit another suggestion
Speaker List Skip to main content Toggle navigation Search Home Speaker List Home Speaker List Speaker List Type here to filter the list Names Organization City State Country All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z M jM M Luther, james Vanderbilt University Nashville, United States TM M Saleem, Tipu Faiz Pennsylvania Institute of Endocrinology, Pennsylvania, United States Lititz, Pennsylvania, United States BM M. Finnerty, Brendan M. Weill Cornell Medicine New York, United States HM Müller, Hermann L. University Children’s Hospital Oldenburg, Germany MM Małecki, Maciej J … uri, United States PM Manroa, Pooja Associate Clinical Professor, Endocrinology fellowship Program Director City of Hope National Medical Center Duarte, United States MM Mansfield, Michael Consultant The Leeds teaching Hospitals NHS Trust Leeds, England, United Kingdom CM Mansilla, Carmen University of San Martín de Porres , Lima, Peru Lima, Peru MM Mansoori, Maryam (she/her/hers) Institute for Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, … ashington, United States RM Matsumoto, Ryusaku Center for iPS Cell Research and Application, Kyoto University Kyoto, Japan RM Matsumoto, Ryusaku Kyoto University Kyoto, Kyoto, Japan MM Matta, Marina N/A Worcester, Massachusetts, United States JM Mattana, Joseph AM Mattarei, Andrea University of Padua Padova, Italy DM Matters, Doreen M. Administrative Manager Duke University School of Nursing Durham, North Carolina, United States JM Matthew, Joshua Medical student MS3 Rutgers
Mitochondrial Efficiency Drives HCC and Offers Therapeutic Target | OrsoBio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
Orsobio ACMSD inhibitor reverses liver injury in preclinical models | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 lan
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
PharmaShots Weekly (Feb 16 Edition) - PharmaShots Subscribe Sign in PharmaShots Weekly (Feb 16 Edition) PharmaShots Feb 16, 2026 1 Share Cover Story A Bold Bet on RNA: Madrigal Expands Its MASH Ambition with Global siRNA Deal Strategic Deals & Innovation Spotlight Lilly’s $2.4B Orna Acquisition Advances Genetic Medicine Iambic–Takeda: AI Accelerates Oncology & GI Innovation Memo–CSL: Rewriting the Recombinant Polyclonal IgG Playbook Insilico–CMS: AI-Powered Expansion in CNS & Autoimmune Formycon–Lotus: Advancing Keytruda Biosimilar Strategy in APAC Clinical Pipeline Highlights Prim
OrsoBio To Advance TLC-6740 After Successful Obesity Combo Trial Pink Sheet Scrip Medtech Insight HBW Insight Generics Bulletin In Vivo Spotlight China Obesity AI Drug Pricing Cell & Gene Therapies Business Deals Financing Earnings Commercial Strategy Approvals & Launches Trial Results Market Access Disease Cancer Immune Disorders Cardiovascular Neurological Rare Diseases Deep Dives Interviews Data Insights Scrip Asks Disease Landscapes Focus On Asia Japan South Korea India Scrip Asia 100 Tools & Trackers Pipeline Watch Finance Watch Deal Watch Stock Watch Top Selling Drugs Company … st Spotify About About Us Opens in new window Meet the Team Editorial Standards Award-Winning Journalism Help Advertise Opens in new window Contact Us Evaluate Home Account My Account My View Email Preferences Start Free Trial Opens in new window More Scrip Perspectives Scrip 100 Ranking Scrip Asia 100 Conferences Executives On The Move Pipeline Watch Terms and Conditions Opens in new window Privacy Policy Opens in new window
Orsobio Inc. - BioCentury Company Profiles - BCIQ About BioCentury Privacy & Legal Contact About BioCentury Company Overview Management Editorial & Research Scientific Advisory Board Privacy & Legal User Agreement Terms of Use Privacy Policy Use of Images & Market Data Reprints & Permissions Contact Contact Us Advertising & Sponsorship Customer Resource Center Career Opportunities Forgot Password © 2026 BioCentury Inc. All Rights Reserved. Copyright © 2026 BioCentury Inc. All Rights Reserved.
OrsoBio's LXR inverse agonist for triglyceride disorders Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Views Webinars Pharma 50 2026 Pharma 50 2025 Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Advertise SUBSCRIBE OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders By Julia Rock-Torcivia | February 23, 2026 OrsoBio, a small biotech company focused on developing therapies for obesity
Science - Restore Energy Balance to Treat Metabolic Disorders Skip to content about team science pipeline news about team science pipeline news Restoring Energy Homeostasis to Treat Severe Metabolic Disorders OrsoBio’s development programs address high unmet medical need in patients with severe metabolic disorders, including obesity, type 2 diabetes, severe hypertriglyceridemia, and MASH. Our programs address the root cause of organ dysfunction by modulating fundamental metabolic pathways with four highly targeted and complementary mechanisms: 0 % Prevalence of obesity in the United States 0 M
Our leadership team has been with OrsoBio since its inception in 2022. Chief Executive Officer G. Mani Subramanian, Chief Medical Officer and Head of Development Rob Myers, MD, and Chief Business and… | OrsoBio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
About - Biopharmaceutical company targeting metabolic disorders Skip to content about team science pipeline news about team science pipeline news About Us OrsoBio is on a mission to redefine the treatment of metabolic diseases by addressing their root cause. OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe metabolic disorders. Our dedicated, highly skilled, and cohesive team of physicians and scientists bring decades of clinical and drug development experience, from academia a
OrsoBio secures funds to develop obesity treatment portfolio Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Me
OrsoBio announces clinical trial progress for TLC-2716 metabolic therapy Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Pro
OrsoBio explores mitochondrial angle on metabolic disorders Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Views Webinars Pharma 50 2026 Pharma 50 2025 Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Advertise SUBSCRIBE Beyond GLP-1: OrsoBio targets mitochondria to treat metabolic disorders from a new and potentially complementary angle By Brian Buntz | February 2, 2024 Emerging from stealth in late 2022, Palo Alto–based biopharm
Team - OrsoBio Skip to content about team science pipeline news about team science pipeline news Meet The Team Leadership Scientific Advisors Board of Directors Team Members Leadership Mani Subramanian, MD, PhD CEO and Founder Rob Myers, MD Chief Medical Officer and Head of Development Gans Ganapati Co-Founder and Chief Business and Financial Officer Scientific Advisors Gerald Shulman, MD, PhD Professor of Medicine, Yale University Johan Auwerx, MD, PhD Professor, École Polytechnique Fédérale de Lausanne Takanori Takebe, MD, PhD Professor, Tokyo Medical and Dental University Board of Director … ne training at University Hospitals of Cleveland (CWRU) and Infectious Diseases fellowship at NIAID, NIH. He holds a PhD degree from University of Michigan and MD from Armed Forces Medical College, India. Linkedin Rob Myers, MD Chief Medical Officer and Head of Development Dr. Myers is a hepatologist with over 20 years’ experience in academia and the biopharmaceutical industry. He was previously Vice President at Gilead Sciences, where he oversaw clinical development in liver … d his MD and Internal Medicine training at Western University, Gastroenterology fellowship at the University of Calgary, and Hepatology fellowship at the Université de Paris VI, and holds a master’s degree in Epidemiology from the University of Calgary. Linkedin Gans Ganapati Co-Founder and Chief Business and Financial Officer Gans Ganapati, Co-Founder and Chief Business and Financial Officer of OrsoBio, brings over 25 years of business leadership experience. He was VP of Cor … ty of Clinical Investigation (ASCI) and recipient of the Robertson Investigator Award from the New-York Stem Cell Foundation Linkedin Srini Akkaraju, MD, PhD Managing General Partner, Samsara BioCapital Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture P … ImmunOs Therapeutics. Prior to joining Samsara, Aditya completed a postdoctoral fellowship at Stanford University where he studied the role of microglia in synapse pruning and cognition in the adult brain, and the role of aberrant neuro-immune signaling in the progression of neurodegenerative disorders. As a graduate student, Aditya studied the r
Ascenta Capital - BIO Investment & Growth Summit 2026 Skip To Main Content February 16-17, 2027 | Miami Beach HOME ABOUT Show submenu for: ABOUT EVENT OVERVIEW WHY ATTEND? FAQS SHARE ON SOCIAL MEDIA CONTACT US SCHEDULE PROGRAM Show submenu for: PROGRAM PROGRAM SPEAKERS ADVISORY COMMITTEE COMPANY PRESENTATIONS PRESENTING COMPANIES BIO Partnering™ Show submenu for: BIO Partnering™ BIO PARTNERING™ PARTICIPATING COMPANIES PARTICIPATING INVESTORS PARTNERING WEBINARS DOWNLOAD THE APP LOG IN TO BIO PARTNERING SPONSOR Show submenu for: SPONSOR Become a Sponsor 2026 Sponsors SEARCH More Show more … u items Ascenta Capital Ascenta Capital is a biotech-focused late-stage venture fund, co-founded in 2023 by Dr. Evan Rachlin and Dr. Lorence Kim. The fund is focused on concentrated investments in companies developing portfolios of therapeutics based on innovative platform technologies. We focus on: + Multi-asset platforms + Companies with PoC As an operator-led team, our team has partnered with ADARx, Iambic, Odyssey, Cardurion, and OrsoBio to date. For more information abou
ENDO 2026 Skip to main content Toggle navigation Search Home Facebook Post Print Cardiovascular Endocrinology ORF30-06 - The Liver X Receptor Inverse Agonist TLC-2716 Reduces Triglycerides, Remnant Cholesterol, and Liver Fat in Patients with Severe Hypertriglyceridemia and Metabolic Dysfunction-Associated Steatotic Liver Disease Sunday, June 14, 2026 2:30 PM - 2:45 PM CT Location: Room W181AB Co-Author(s) RA Raúl A. Aguilar Orozco, MD Hospital General de Occidente Zapopan, Jalisco, Mexico AL Alma L. Ladrón de Guevara Cetina, MD Centro de Investigacion y Gastroenterologia S.C. Cuauhtemoc, Estad
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.